Skip to content

Study · Ex vivo tissue · 1996

16 results

Protein kinase C-dependent growth hormone releasing peptides stimulate cyclic adenosine 3',5'-monophosphate production by human pituitary somatotropinomas expressing gsp oncogenes: evidence for crosstalk between transduction pathways.

Adams EF, Lei T, Buchfelder M, Bowers CY, Fahlbusch R

Molecular endocrinology (Baltimore, Md.)1 Apr 1996Cited by 35 (Europe PMC)

PMID8721987 (opens in a new tab)DOI10.1210/mend.10.4.8721987 (opens in a new tab)PepBankPUB-08721987
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

12 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueMechanism

    In cultured human somatotropinomas with gsp oncogenes, GHRP‑2 stimulated cAMP production.

    In plain wordsIn cultured human pituitary tumor cells that carry gsp oncogenes, GHRP‑2 raised cAMP production.

    Peptide
    GHRP-2
    Outcome
    IncreasecAMP production in tumors with gsp oncogenes
    Study

    humann = 7

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides stimulated cAMP production in the latter but not former types of tumor.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  2. 02LabEx vivo tissueMechanism

    In cultured human somatotropinomas with gsp oncogenes, GHRP‑6 stimulated cAMP production.

    In plain wordsIn cultured human pituitary tumor cells that carry gsp oncogenes, GHRP‑6 raised cAMP production.

    Peptide
    GHRP-6
    Outcome
    IncreasecAMP production in tumors with gsp oncogenes
    Study

    humann = 7

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides stimulated cAMP production in the latter but not former types of tumor.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  3. 03LabEx vivo tissueMechanism

    In cultured human somatotropinomas, GHRP‑2 dose-dependently stimulated the rate of phosphatidylinositol hydrolysis.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑2 increased phosphatidylinositol hydrolysis, a cell signaling step, with higher doses.

    Peptide
    GHRP-2
    Outcome
    IncreasePhosphatidylinositol hydrolysis rate
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides dose-dependently stimulated the rate of PI hydrolysis and GH secretion by cell cultures of both types of somatotropinoma.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  4. 04LabEx vivo tissueMechanism

    In cultured human somatotropinomas, GHRP‑6 dose-dependently stimulated the rate of phosphatidylinositol hydrolysis.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑6 increased phosphatidylinositol hydrolysis, a cell signaling step, with higher doses.

    Peptide
    GHRP-6
    Outcome
    IncreasePhosphatidylinositol hydrolysis rate
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides dose-dependently stimulated the rate of PI hydrolysis and GH secretion by cell cultures of both types of somatotropinoma.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  5. 05LabEx vivo tissueActivity measurement

    In cultured human somatotropinomas, GHRP‑2 dose-dependently stimulated GH secretion.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑2 increased growth hormone release with higher doses.

    Peptide
    GHRP-2
    Outcome
    IncreaseGH secretion
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides dose-dependently stimulated the rate of PI hydrolysis and GH secretion by cell cultures of both types of somatotropinoma.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  6. 06LabEx vivo tissueActivity measurement

    In cultured human somatotropinomas, GHRP‑6 dose-dependently stimulated GH secretion.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑6 increased growth hormone release with higher doses.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH secretion
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides dose-dependently stimulated the rate of PI hydrolysis and GH secretion by cell cultures of both types of somatotropinoma.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  7. 07LabEx vivo tissueActivity measurement

    In cultured human somatotropinomas, GHRP‑2 was considerably more potent than GHRP-6.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑2 was considerably more potent than GHRP-6.

    Peptide
    GHRP-2
    Outcome
    IncreasePotency compared with GHRP-6
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Comparator
    GHRP-6
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRP-2 was considerably more potent than GHRP-6.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  8. 08LabEx vivo tissueActivity measurement

    In cultured human somatotropinomas, GHRP‑6 was considerably less potent than GHRP-2.

    In plain wordsIn cultured human pituitary tumor cells, GHRP‑6 was considerably less potent than GHRP-2.

    Peptide
    GHRP-6
    Outcome
    DecreasePotency compared with GHRP-2
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Comparator
    GHRP-2
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GHRP-2 was considerably more potent than GHRP-6.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  9. 09LabEx vivo tissueMechanism

    In cultured human somatotropinomas without gsp oncogenes, GHRP‑2 did not stimulate cAMP production.

    In plain wordsIn cultured human pituitary tumor cells without gsp oncogenes, GHRP‑2 did not raise cAMP production.

    Peptide
    GHRP-2
    Outcome
    No significant changecAMP production in tumors without gsp oncogenes
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides stimulated cAMP production in the latter but not former types of tumor.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  10. 10LabEx vivo tissueMechanism

    In cultured human somatotropinomas without gsp oncogenes, GHRP‑6 did not stimulate cAMP production.

    In plain wordsIn cultured human pituitary tumor cells without gsp oncogenes, GHRP‑6 did not raise cAMP production.

    Peptide
    GHRP-6
    Outcome
    No significant changecAMP production in tumors without gsp oncogenes
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both peptides stimulated cAMP production in the latter but not former types of tumor.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  11. 11LabEx vivo tissueMechanism

    In cultured human somatotropinomas without gsp oncogenes, GHRP‑2 potentiated the cAMP production induced by GHRH and PACAP.

    In plain wordsIn cultured human pituitary tumor cells without gsp oncogenes, GHRP‑2 increased the cAMP rise caused by GHRH and PACAP.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRH- and PACAP-induced cAMP production in tumors without gsp oncogenes
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Comparator
    GHRH or PACAP alone
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, GHRP-2 and GHRP-6 potentiated the stimulation of cAMP production induced by GHRH and pituitary adenylate cyclase-activating polypeptide in tumors without gsp oncogenes.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.
  12. 12LabEx vivo tissueMechanism

    In cultured human somatotropinomas without gsp oncogenes, GHRP‑6 potentiated the cAMP production induced by GHRH and PACAP.

    In plain wordsIn cultured human pituitary tumor cells without gsp oncogenes, GHRP‑6 increased the cAMP rise caused by GHRH and PACAP.

    Peptide
    GHRP-6
    Outcome
    IncreaseGHRH- and PACAP-induced cAMP production in tumors without gsp oncogenes
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Comparator
    GHRH or PACAP alone
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Moreover, GHRP-2 and GHRP-6 potentiated the stimulation of cAMP production induced by GHRH and pituitary adenylate cyclase-activating polypeptide in tumors without gsp oncogenes.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 13LabNot a test of GHRP-2 aloneEx vivo tissueActivity measurement

    In cultured human somatotropinomas, the effects of GHRP‑2 on GH secretion were reduced or abolished by the PKC inhibitor phloretin and the calmodulin inhibitor W7.

    In plain wordsIn cultured human pituitary tumor cells, blocking protein kinase C or calmodulin reduced or stopped the growth hormone release caused by GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH secretion after phloretin and W7
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The effects on GH secretion were reduced or abolished by phloretin, an inhibitor of protein kinase C, and W7, an inhibitor of calmodulin.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 14LabNot a test of GHRP-6 aloneEx vivo tissueActivity measurement

    In cultured human somatotropinomas, the effects of GHRP‑6 on GH secretion were reduced or abolished by the PKC inhibitor phloretin and the calmodulin inhibitor W7.

    In plain wordsIn cultured human pituitary tumor cells, blocking protein kinase C or calmodulin reduced or stopped the growth hormone release caused by GHRP‑6.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH secretion after phloretin and W7
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The effects on GH secretion were reduced or abolished by phloretin, an inhibitor of protein kinase C, and W7, an inhibitor of calmodulin.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 15LabNot a test of GHRP-2 aloneEx vivo tissueActivity measurement

    In cultured human somatotropinomas, antagonism of the GHRH receptor and of protein kinase A did not alter the stimulatory effect of GHRP‑2 on GH secretion.

    In plain wordsIn cultured human pituitary tumor cells, blocking the GHRH receptor or protein kinase A did not change how GHRP‑2 raised growth hormone release.

    Peptide
    GHRP-2
    Outcome
    No significant changeGH secretion after GHRH-receptor and PKA antagonism
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    However, antagonism of the GHRH-receptor and of protein kinase A with (N-Ac-Tyr1,D-Arg2)GRF-(1-29)-NH2 and Rp-adenosine-3',5'-cyclic monophosphothioate, respectively, did not alter the stimulatory effects of GHRP-2 and GHRP-6 on GH secretion.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  4. 16LabNot a test of GHRP-6 aloneEx vivo tissueActivity measurement

    In cultured human somatotropinomas, antagonism of the GHRH receptor and of protein kinase A did not alter the stimulatory effect of GHRP‑6 on GH secretion.

    In plain wordsIn cultured human pituitary tumor cells, blocking the GHRH receptor or protein kinase A did not change how GHRP‑6 raised growth hormone release.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH secretion after GHRH-receptor and PKA antagonism
    Study

    humann: not reported in source

    Cell cultures of human pituitary somatotropinomas
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    However, antagonism of the GHRH-receptor and of protein kinase A with (N-Ac-Tyr1,D-Arg2)GRF-(1-29)-NH2 and Rp-adenosine-3',5'-cyclic monophosphothioate, respectively, did not alter the stimulatory effects of GHRP-2 and GHRP-6 on GH secretion.
    2 context sentences
    Summary · context
    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes.
    Summary · context
    The effect of GHRP-2 and/or GHRP-6 on cAMP production was studied in 15 tumors, seven of which possessed constitutive adenylyl cyclase activity as evidenced by presence of gsp oncogenes.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Versions 2 to 3

    13 Oct 2026, 16:31 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:13 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.